secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTELLIGENT BIO SOLUTIONS INC. (INBS)
CIK:        0001725430
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001493152-25-005677
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INBS reports prelim Q2 revenue ~$0.61M; gross margin up to 38.5%; FDA 510(k) submitted for U.S. market entry in 2025
--------------------------------------------------------------------------------

- Preliminary Q2 FY2025 revenue ~$0.61M; 6-month revenue ~$1.48M; gross profit margin improved to 38.5% from 27.7%.
- Fiscal year 2024 revenues grew 148% YoY; over 400 accounts in 19 countries with customer employee base ~1.4M.
- Submitted 510(k) pre-market notification to FDA in Dec 2024; on track for U.S. market entry in 2025.
- PK study showed fingerprint sweat correlates with blood at 95% confidence; Method Comparison Study showed ~94% accuracy.
- Gross profit up 32.6% to $0.57M for six months; strategic focus on higher-margin cartridge sales driving margin expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725430/000149315225005677/0001493152-25-005677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725430/000149315225005677/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-005677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer